Physician profile
Lino Lamb
NPI 1588212575
$3,016.18
in general payments reported to CMS, 2019-2025
18 companies · $2,766 in 2025
The $2,766 reported for 2025 was more than what 97% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $160 · 2024: $89.42 · 2025: $2,766.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,931 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,931.19 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $729.39 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.34 | 2023-2025 | Xifaxan, Relistor, Trulance |
| Janssen Biotech, INC. | $486.93 | 2025 | Tremfya |
| Aimmune Therapeutics, INC. | $260.40 | 2024-2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $249.64 | 2025 | Iqirvo |
| Madrigal Pharmaceuticals | $149.57 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $124.95 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $96.36 | 2025 | Dupixent |
| Lilly USA, LLC | $72.14 | 2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $60.69 | 2025 | |
| Ardelyx, INC. | $51.26 | 2025 | Ibsrela |
| Gilead Sciences, INC. | $50.04 | 2025 | |
| Phathom Pharmaceuticals, INC. | $33.34 | 2024-2025 | Voquezna |
| Globus Medical, INC. | $27.86 | 2025 | Senza |
| Medtronic, INC. | $18.50 | 2025 | Interstim |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $16.59 | 2025 | Entyvio |
| Novo Nordisk INC | $15.71 | 2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $6.47 | 2025 | Stelara, Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lino Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.